Biosimilar substitution in France: no way back?
Beginning on 1 January 2014, French pharmacists are now legally permitted to substitute a biosimilar for the prescribed (reference) biological medicine as long as the prescribing physician has not marked the prescription as ‘non-substitutable’.
According to the new law, substitution is allowed only when initiating a course of treatment and if the biosimilar belongs to the same group as the prescribed product, known as a ‘similar biologic group’. These groups will be drawn up by French healthcare authority ANSM.
However, as (i) the criteria for inclusion in a ‘similar biologic group’ by the ANSM, (ii) the procedure for registration on the biosimilar register (entitled ‘list of reference of similar biologic groups’) and the content of that list and (iii) the precise conditions for biosimilar substitution by a pharmacist remain to be further defined in decrees from the Administrative Supreme Court, biosimilar substitution should only occur in practice after these decrees have been adopted…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from The Lawyer
Analysis from The Lawyer
Which firms are cutting it in this era of slimline rosters, and who are the GC new brooms making clean sweeps? The Lawyer can reveal all
At the time of its launch Accutrainee was described as a revolutionary change to the training model. Has it proved to be so? Not really.